Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
Date:7/14/2008

d other current assets 1,208,000 1,188,000

Total current assets 19,843,000 19,898,000

PROPERTY:

Leasehold improvements 669,000 646,000

Laboratory equipment 4,140,000 3,533,000

Furniture, fixtures and computer equipment 919,000 873,000

5,728,000 5,052,000

Less accumulated depreciation and

amortization (3,670,000) (3,212,000)

Property, net 2,058,000 1,840,000

Other assets 1,156,000 1,259,000

TOTAL ASSETS $23,057,000 $22,997,000

-continued-

PEREGRINE PHARMACEUTICALS, INC.

CONSOLIDATED BALANCE SHEETS

AS OF APRIL 30, 2008 AND 2007 (continued)

2008 2007

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:

Accounts payable $2,060,000 $1,683,000

Accrued clinical trial site fees 237,000 228,000

Accrued legal and accounting fees 450,000 392,000

Accrued royalties and license fees 222,000 337,000

Accrued payroll and related costs 1,084,000 874,000

Notes payable, current portion - 379,000

Capital lease obligation, current portion 22,000 17,000

Deferred revenue 2,196,000 1,060,000

Customer deposits 838,000 585,000

Other current liabilities 331,000 300,000

Total current liabilities 7,440,000 5,855,000 '/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
2. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
3. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
4. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
7. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
11. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Three Lawrence Livermore researchers have received ... R&D Award for their research in producing ... , Shared with collaborators from the National Renewable ... Las Vegas (UNLV), the award recognizes the team ... production and corrosion processes. , These models have ...
(Date:8/28/2014)... SAN DIEGO, California, USA (PRWEB) August 28, 2014 ... at the Department of Physics and Optical Science and ... at the University of North Carolina at Charlotte, and ... has been elected to serve as the 2015 Vice ... photonics. , SPIE 2014 President Philip Stahl announced recent ...
(Date:8/28/2014)... A new research platform uses a ... tiny structures undergoing stress and heating, an ... designs for microelectronics and batteries., This new ... about how heating and the surface stress ... Researchers have discussed the merits of surface-stress ...
(Date:8/28/2014)... Aug. 28, 2014  Next month, executives from clinical trial ... industry events beginning with Patient-Centered Clinical Trials 2014 , ... Boston , September 4-5. Patient recruitment experts ... Aaron Fleishman will share insights on the benefits of ... of tactics – from media to mobile apps – can ...
Breaking Biology Technology:Livermore Team Awarded for Hydrogen Production Research 2Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3BBK Worldwide Leads Sessions at Key September Events 2
... , , SAN DIEGO, Sept. 2 ... OPTR ) lead developmental product candidates will be ... and Chemotherapy (ICAAC) to be held at The Moscone Center in San ... http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO ) , , , ...
... , NEW YORK, Sept. 1 Bile ... energy metabolism. Bile acid activation of the G protein-coupled receptor TGR5 has ... conferring resistance to weight gain. Now, a paper published in the current ... 2009) elaborates on a separate TGR5-regulated mechanism in the gut that drives ...
... , , SAN FRANCISCO, ... a different story in August as the Burrill Biotech Select Index suffered ... 1.1 percent. The broader markets, on the other hand, continued their upward ... and the Nasdaq closing up 1.5 percent. , , ...
Cached Biology Technology:Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting 2Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting 3Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity 2Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity 3Biotech Cools Off in August But Capital Markets Remain Positive 2Biotech Cools Off in August But Capital Markets Remain Positive 3Biotech Cools Off in August But Capital Markets Remain Positive 4
(Date:8/29/2014)... Scientists at the Barshop Institute for Longevity and Aging ... UT Health Science Center at San Antonio, have found ... longest-lived rodent, the naked mole rat. , They ... mole rats protects and alters the activity of the ... , The factor also protects proteasome function in human, ...
(Date:8/29/2014)... researcher from the University of Texas Medical Branch at Galveston ... monoclonal antibodies can completely protect monkeys against a lethal dose ... a time when the disease is severe. , Thomas Geisbert, ... Nature discussing advances in Ebola treatment research. The ... the most deadly of pathogens, with fatality rates of up ...
(Date:8/29/2014)... connections in transcription factor networks (TFNs) to evaluate the ... in PLOS Computational Biology in August. ... a network,s resilience against mutations. , "In simulations, ... models has a greater effect on robustness than varying ... Dov A. Pechenick, PhD, lead author and former researcher ...
Breaking Biology News(10 mins):Factor in naked mole rat's cells enhances protein integrity 2Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Assortativity signatures of transcription factor networks contribute to robustness 2
... might find it progressively harder to navigate the maze of ... short-term exposure to vehicle pollution, mice showed significant brain damage ... The mind-numbing toxin is not an exhaust gas, but ... and weathering of car parts and pavement, according to the ...
... A groundbreaking clinical study of a new method for preventing ... the medical journal Ultrasound in Obstetrics & Gynecology , ... ( The peer-reviewed findings were led by the Perinatology ... the Wayne State University School of Medicine at Hutzel Hospital ...
... (April 6, 2011) -- Most people experience X-ray computed tomography (CT) ... clot. But in the lab of Dr. Quin Liu, PhD., in ... of CT scanners as part of an agriculture study to increase ... went little potted rice plants in an automated facility that could ...
Cached Biology News:Freeway air bad for mouse brain 2Major breakthrough in preventing premature birth announced by NIH/WSU 2Major breakthrough in preventing premature birth announced by NIH/WSU 3Seeing rice with X-rays may improve crop yields 2
...
BD BioCoat Poly-D-Lysine 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine....
... ProteinChip System, Series 4000 incorporates the critical ... and biologists in biomarker research. The Series ... route for converting biomarker discoveries to biomarker ... Series 4000 is designed to fit into ...
Gelatin 100 mm Culture Dishes...
Biology Products: